Longitude (Cayman)’s Acadia Pharmaceuticals ACAD Stock Holding History

Longitude (Cayman)’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-15,000	Closed	-$211K	–	63
2022 Q2	$211K	Hold	15,000	–	–	0.31%	50
2022 Q1	$363K	Sell	15,000 -30,000	-67%	-$726K	0.34%	40
2021 Q4	$1.05M	Sell	45,000 -35,000	-44%	-$704K	0.56%	38
2021 Q3	$1.33M	Buy	+80,000	New	+$1.54M	0.59%	37
2021 Q2	–	Sell	-10,000	Closed	-$258K	–	58
2021 Q1	$258K	Buy	+10,000	New	+$440K	0.1%	53

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Longitude (Cayman)'s ACAD Position: Q2 2022 in Review

Longitude (Cayman) sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 45,000 shares — an estimated $840K sold.

Longitude (Cayman) first reported a position in ACAD in Q4 2020 and held it in 6 quarters. The position peaked at $6.13M in Q4 2020. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

Longitude (Cayman) reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Longitude (Cayman) sold 45,000 Acadia Pharmaceuticals shares in Q2 2022, an estimated $840K.
Longitude (Cayman) first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 6 quarters.
Longitude (Cayman)'s Acadia Pharmaceuticals position peaked at $6.13M in Q4 2020.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on Longitude (Cayman)'s 13F filing for Q2 2022, filed 12 Aug 2022.